S-217622，一种 3CL 蛋白酶抑制剂，也是用于 SARS-CoV-2 的临床候选药物。
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2.
机构信息
School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.
出版信息
J Med Chem. 2022 May 12;65(9):6496-6498. doi: 10.1021/acs.jmedchem.2c00624. Epub 2022 May 4.
PMID:35507419
Abstract
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.
摘要
新型冠状病毒肺炎（COVID-19）大流行凸显了科学家应对世界面临的巨大挑战的快速反应能力。目前，口服 3C 蛋白酶抑制剂 S-217622 正在进行临床试验，本文介绍了由 Shionogi 和北海道大学通过基于结构的药物设计、筛选和优化发现该药物的过程。
Zotero 插件